Cytokine Armoring based Next-Generation TIL Development Services

The Urgent Need for Next-Generation TIL Development

Tumor-infiltrating lymphocyte (TIL) treatment is a potential cancer immunotherapy that employs the patient's T cells to target and eradicate tumor cells. Its advantages such as excellent specificity, broad target identification, strong tumor tropism, etc., making it an appropriate therapy for a variety of solid tumors. However, its clinical advantages have been limited by effectiveness issues and safety concerns. To overcome these challenges, developing more effective and safer TILs is critical for improving clinical feasibility and expanding TIL therapy's applicability to a larger patient group.

Cytokine Armoring based Next-Generation TIL Development Service at Creative Biolabs

Cytokines play an important role in regulating immune responses and cellular function. TILs armored with cytokines represent a significant advancement in cancer immunotherapy. To aid in cancer therapy research, Creative Biolabs delivers an innovative and robust cytokine armoring based next-generation TIL development service for clients around the world. We take advantage of advanced gene editing technologies to modify TILs to enhance their anti-tumor activity and overcome the challenges associated with solid tumor microenvironments. This strategy empowers TILs to function more effectively within the complex tumor microenvironment, ultimately leading to improved therapeutic outcomes for cancer patients.

Fig.1 The dynamics of cytokines in the immune-cancer cycle.¹

Throughout this service, we provide a full range of services from TIL isolation, engineering, amplification, to verification, and the entire process strictly follows GMP regulatory standards. Initially, we employ advanced single-cell sequencing and other methods to eliminate possible tumor-specific killer cells. Then, through gene editing technologies, we introduce or knock out specific cytokine genes to enhance anti-tumor efficacy while reducing adverse effects. Following in vitro activation and amplification, we apply a series of ELISA, staining, qPCR, and other technologies to comprehensively validate the quality and vitality of engineered TILs, ensuring that each client receives high-quality and efficient TIL products. With the support of our robust platform and experienced team of scientists, we also provide service to support clients' TIL projects in preclinical and clinical studies, guaranteeing the maximum customer benefits in the shortest possible time.

For different cytokine assembly strategies, we provide precise and targeted comprehensive services to meet the different needs of clients, which include:

• Cytokine-Secreting based Next-generation TIL Development Service
• Autocrine Loop based Next-Generation TIL Development Service

Fig.2 The general process of next-generation TIL development.

How Cytokine Armoring Enhances TIL Therapy

• Enhanced Tumor Cell Killing: Directly enhance the cytotoxic activity of TILs & Recruit additional immune cells to the tumor site.
• Overcoming Immune Suppression: Inhibitory checkpoint blockade & Immune-suppressive cell inactivation
• Improved TIL Persistence: Promote the proliferation and survival of TILs, leading to more sustained anti-tumor effects.

Diverse and Selective Cytokine Profiles for Next-generation TIL Development

We provide diverse cytokine types to choose from for clients' TIL development projects, such as:

Fig.3 Selective cytokine profiles.

Our Service Advantages

• Advanced Technology Platform
• Experienced Scientific Team
• Customized Development Plans
• Accelerated Development Timeline
• Regulatory Expertise
• Comprehensive Service Offerings

Frequently Asked Questions

Q1: What types of tumors are suitable for cytokine-armored TIL therapy?

A1: Cytokine-armored TIL therapy has the potential to treat a wide range of solid tumors, including but not limited to melanoma; renal cell carcinoma, non-small cell lung cancer, colorectal cancer, ovarian cancer, etc. For different tumor types, Creative Biolabs provides customized development strategies and schemes to empower the specificity and efficacy in targeted tumor killing.

Q2: What do clients need to do to start with a cytokine-armored next-generation TIL development project?

A2: To initiate a cytokine-armored TIL development project, please contact Creative Biolabs. Our experienced team will work closely with you to discuss your specific needs, develop a customized project plan, and provide a detailed proposal.

Are you interested in our cytokine armoring based next-generation TIL development service? Please contact us promptly. We are always available to answer your inquiries and discuss your unique requirements.

Reference

1. Yi, Ming, et al. "Targeting cytokine and chemokine signaling pathways for cancer therapy." Signal transduction and targeted therapy 9.1 (2024): 176. Distributed under Open Access License CC BY 4.0, without modification.